Ocular Therapeutix Inc Stock News
$9.22
2.54%
yesterday
Nasdaq,
Jun 27, 10:03 pm CET
Ocular Therapeutix Inc Stock News
Neutral
GlobeNewsWire
●
2 days ago
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience
Neutral
GlobeNewsWire
●
12 days ago
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.
Neutral
GlobeNewsWire
●
about 2 months ago
BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.
Neutral
GlobeNewsWire
●
3 months ago
BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements materi...
Neutral
GlobeNewsWire
●
3 months ago
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
Positive
The Motley Fool
●
4 months ago
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
Positive
Seeking Alpha
●
4 months ago
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Neutral
Seeking Alpha
●
4 months ago
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
